MedCity News January 15, 2026
Bispecific antibodies are one of the hottest areas for drug research and dealmaking, and several of them were discussed this week during the annual J.P. Morgan Healthcare Conference in San Francisco. Takeda President, Research and Development, Andy Plump talked to MedCity News about what sets the Japanese pharma company’s newly licensed drug apart.
Pharmaceutical companies need to spend money in order to make money, and the looming loss of patent exclusivity for numerous products has these companies out in force striking business deals to fill their pipelines with new drugs offering blockbuster potential. A recent report tallied $36 billion splashed out by big pharma in business deals in October and November alone.
One of those deals was the $1.2 billion...
Today's Sponsors
Today's Sponsor